Artivion（AORT）今日盘中股价大跌35.54%，引起了市场的广泛关注。
消息面上，华尔街分析师在周五发布的研究报告中下调了Artivion的目标股价。其中，Canaccord Genuity将Artivion的目标价从48美元下调至36美元，奥本海默（Oppenheimer）亦将其目标价从50美元下调至38美元。分析师下调目标价通常反映了对公司未来盈利前景或估值的担忧，这直接影响了投资者的信心，导致了股价在盘中交易时段大幅下挫。
Artivion是一家专注于心血管外科修复和重建的医疗设备公司。分析师目标价的下调可能与对公司近期业绩、市场竞争或监管环境变化的评估有关。此类评级调整往往是股价短期波动的重要催化剂。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.